We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » CRISPR Therapeutics Reports Positive Phase 1 Data for CAR-T Treatment
CRISPR Therapeutics Reports Positive Phase 1 Data for CAR-T Treatment
CRISPR Therapeutics has reported positive results for a phase 1 study evaluating CTX110, its chimeric antigen receptor (CAR) T-cell therapy for the treatment of relapsed or refractory nonHodgkin’s lymphoma in patients who have received at least two prior lines of therapy.